✨ Free AI Report
Idorsia Pharmaceuticals Ltd: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Idorsia Pharmaceuticals Ltd
Company Research

Idorsia Pharmaceuticals Ltd: Business Overview, Financials & Competitive Analysis

Idorsia is a Swiss biopharmaceutical company specializing in discovering, developing, and commercializing innovative small-molecule medicines for unmet medical needs in CNS, cardiovascular, immunological, and orphan d...

Analyst-debate audio for Idorsia Pharmaceuticals Ltd

AskCyborg analysts argue the bull and bear cases for Idorsia Pharmaceuticals Ltd across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Idorsia represents a turnaround story in biotech with commercialized products and strategic partnerships offsetting previous...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals/Small-Molecule Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Idorsia Pharmaceuticals Ltd Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Idorsia Pharmaceuticals Ltd Overview

Pro stress-test →

Idorsia is a Swiss biopharmaceutical company specializing in discovering, developing, and commercializing innovative small-molecule medicines for unmet medical needs in CNS, cardiovascular, immunological, and orphan disease areas. Spun out from Actelion following its 2017 acquisition by Johnson & Johnson, Idorsia operates from the Basel region and maintains a highly experienced drug development team.

Strategic Profile

Pro stress-test →

The company is positioned as a specialized small-molecule drug discovery engine with a diversified portfolio including commercialized products (QUVIVIQ for insomnia, TRYVIO/JERAYGO for resistant hypertension) and multiple clinical-stage assets. Idorsia leverages strategic partnerships with major players including Janssen Biotech, Viatris, and Neurocrine Biosciences to maximize portfolio value and reduce development risk.

Competitive Landscape

Pro stress-test →

Idorsia competes in the specialty pharmaceutical space against larger competitors including Galapagos, Neurocrine Biosciences, and other biotech firms developing CNS and cardiovascular therapies. The company differentiates through its focus on small-molecule drug discovery, European biotech hub positioning, and partnership-driven portfolio approach rather than full capitalization of development programs.

Industry Context

Idorsia Pharmaceuticals Ltd operates in Biopharmaceuticals/Small-Molecule Drug Development.

Key facts

Founded: 2017 · Headquarters: Allschwil, Switzerland · Employees: 552 · Revenue: $273M · Market cap: $1.17B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Idorsia Pharmaceuticals Ltd.

  • Commercial validation achieved with QUVIVIQ (daridorexant) approval for insomnia treatment, representing shift from pre-commercial to revenue-generating biotech
  • Strategic partnerships with major pharma (Janssen, Viatris, Neurocrine) reduce capital burn and execution risk while maintaining upside participation
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • 2025Trailing 12-month revenue of $273M as of September 2025
  • 2023Sold Japan and South Korea operations to Sosei Heptares for CHF 400 million to improve financial position
  • +1 moreTrack every material event for Idorsia Pharmaceuticals Ltd as it happens. Explore monitoring →
Get alerted when Idorsia Pharmaceuticals Ltd has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Small-molecule neuropsychiatric therapiesNeuroscience and psychiatry-focused biopharmaceutical company→Specialty immunology and inflammationBelgium-based biotechnology company focusing on immunology and inflammation→Insomnia and sleep disorder treatmentsMajor pharma collaborator on aprocitentan development→

Compare Idorsia Pharmaceuticals Ltd with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Idorsia Pharmaceuticals Ltd operates in Biopharmaceuticals/Small-Molecule Drug Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals/Small-Molecule Drug Development research →
NEW · MCP server

Ask your AI assistant about Idorsia Pharmaceuticals Ltd

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Idorsia Pharmaceuticals Ltd and its top competitor on Cyborg Score”
“What did Idorsia Pharmaceuticals Ltd do this quarter?”
“Is Idorsia Pharmaceuticals Ltd a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Idorsia Pharmaceuticals Ltd do?+
Idorsia is a Swiss biopharmaceutical company specializing in discovering, developing, and commercializing innovative small-molecule medicines for unmet medical needs in CNS, cardiovascular, immunological, and orphan d...
What is Idorsia Pharmaceuticals Ltd's Cyborg Score?+
Idorsia Pharmaceuticals Ltd has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Idorsia Pharmaceuticals Ltd's main competitors?+
Named competitors include Small-molecule neuropsychiatric therapies, Specialty immunology and inflammation, Insomnia and sleep disorder treatments. The full competitive landscape is in the AskCyborg report.
How can I get the full Idorsia Pharmaceuticals Ltd research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Idorsia Pharmaceuticals Ltd research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Idorsia Pharmaceuticals Ltd over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score